Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Invests In China Oncology Start-up BeiGene

This article was originally published in PharmAsia News

Executive Summary

Merck & Co. affiliate MSD has invested an undisclosed amount of debt and equity financing in the Beijing-based start-up biotech BeiGene, Ltd., BeiGene announced May 2

You may also be interested in...



BeiGene Raises New Funds For Oncology Pipeline

Chinese bioventure BeiGene has raised additional funding from existing and new investors, providing it with new resources to take forward through early clinical trials several molecules for cancer.

BeiGene Raises New Funds For Oncology Pipeline

Chinese bioventure BeiGene has raised additional funding from existing and new investors, providing it with new resources to take forward through early clinical trials several molecules for cancer.

BeiGene CEO John Oyler On Investing In Biotech In China: An Interview With PharmAsia News (Part 2 of 2)

BeiGene CEO John Oyler discusses what is missing in China’s venture capital environment if it truly wants to foster innovation. Based in Beijing, BeiGene’s lead product entered the clinic in 2013.

Related Content

UsernamePublicRestriction

Register

SC077989

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel